Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. Investors Hangout MVP's Message Board

Peregrine shares blasted after trial 'discrepancie

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 99248
Posted On: 09/24/2012 8:28:32 AM
Avatar
Posted By: fitzkarz
Re: fitzkarz #13463

Peregrine shares blasted after trial 'discrepancies' discredit lung cancer data



September 24, 2012 | By John Carroll




Share

Email LinkedIn

Tools


  • Comment

  • Print

  • Contact Author

  • Reprint




Two weeks ago shares of Peregrine Pharmaceuticals ( $PPHM ) skyrocketed on the upbeat survival data it released from a mid-stage study of its lung cancer drug bavituximab. This morning the share price disintegrated after the biotech said the data were unreliable, blaming an unnamed outsourcer for "major discrepancies" found in the distribution of clinical trial supplies used in the study.


Within minutes Peregrine's shares tumbled 80%.


"As part of the trial's execution, Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according to established procedures," Peregrine announced in a release. "A subsequent review of information has determined that the source of these discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product."









Biosimilar regulations and CMOs


Webinar: Now available on-demand

Biosimilar legislation passed in 2010 guaranteed 12 years of patent protection to biotechs from biosimilar competition. But passing the law was the easy part. As FDA hashes out regulations to implement the law, we help CMOs understand the significance of the legislation to their businesses and how the new legislation may help, or hurt, contract manufacturing for biologics. Register Now!








Sign up for our FREE newsletter for more news like this sent to your inbox!

As FierceBiotech reported on September 7 , Peregrine had reported that non-small cell lung cancer patients in the experimental drug arm lived for a median 12.1 months. In the chemo arm, the survival rate was about half that. But the progression-free survival rate was only 4.2 months, causing a number of analysts to question the data on Twitter as they compared a high OS rate with a low PFS. Peregrine enrolled 121 patients for the study. Peregrine also took a beating back in March, when the PFS rate it tracked on bavituximab came close to the rate tracked in the placebo group.


The biotech said it became aware of the discrepancies in the study as it began to prepare for a post-study sit-down with the FDA. Peregrine had been investigating bavituximab as a potential second-line treatment for non-small cell lung cancer. And Peregrine added that the dark cloud now hanging over its Phase II trial would have no impact on other ongoing studies.


- here's the press release


Related Articles:
Peregrine soars on promising survival data for lung cancer drug
Disappointing cancer data triggers sharp drop in Peregrine shares
Peregrine posts promising data on Phase II lung cancer trial
Peregrine shares jump after drug demos brain cancer efficacy





Read more: Peregrine shares blasted after trial 'discrepancies' discredit lung cancer data - FierceBiotech http://www.fiercebiotech.com/story/peregrine-...z27ODnkJHD
Subscribe: http://www.fiercebiotech.com/signup?sourcefor...rceBiotech



(0)
(0)




I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us